Pneumology - Original Articles
3 September 2025
Early Access
Non-invasive profiling of KRAS mutations in lung cancer using droplet digital polymerase chain reaction
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
226
Views
82
Downloads
Authors
With rising cases of lung cancer worldwide, liquid biopsies are becoming increasingly popular as clinically relevant potential non-invasive alternatives to tissue-based biopsies. The principle of partitioning utilized by the droplet digital polymerase chain reaction (ddPCR) makes it a highly sensitive technique for detecting rare tumor-derived mutations in blood. The presence of KRAS mutations is a negative prognostic marker for tyrosine kinase inhibitor (TKI) therapy in lung cancer; hence, profiling of major KRAS mutations before treatment is very crucial for the success of TKI therapy. This study was aimed at profiling three major KRAS mutations, namely G12D (GGT→GAT), G12V (GGT→GTT), and G13D (GGC→GAC) in lung cancer patients using ddPCR. ddPCR assays that rely on probe-based chemistry were standardized for KRAS G12D, KRAS G12V, and KRAS G13D mutations using cfDNA extracted from the patient’s blood. To determine the concordance, blood-derived cfDNA and tumor DNA were compared using ddPCR. A positivity rate of 81.67% for KRAS mutations was observed in the cohort analyzed. KRAS mutations in the cfDNA from blood were effectively detected by ddPCR even at low fractional abundance. Moreover, a comparison of blood-derived cfDNA and tumor-derived genomic DNA-based analysis revealed a concordance of 66.67%, suggesting tumor heterogeneity as the probable reason for the lack of total concordance between the data. This study highlights the usefulness of ddPCR as a prospective clinical tool in oncology and liquid biopsy using blood cfDNA. It can be considered a better alternative to tissue biopsies and mutation profiling of candidate genes, particularly those that are linked to therapeutic response to TKIs.
Altmetrics
Downloads
Download data is not yet available.
Citations
WHO. Cancer. Available from: https://www.who.int/health-topics/cancer#tab=tab_1. Accessed on: 10/05/2024.
Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances, Transl. Lung Cancer Res 2016;5:288-300. DOI: https://doi.org/10.21037/tlcr.2016.06.07
Pinheiro G, Pereira T, Dias C, et al. Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS. Sci Rep 2020;10:3625. DOI: https://doi.org/10.1038/s41598-020-60202-3
Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged?, Nat Rev Drug Discov 2020;19:533-52. DOI: https://doi.org/10.1038/s41573-020-0068-6
Yao R, Yu T, Xu Y, et al. Concurrent somatic KRAS mutation and germline 10q22. 3-q23. 2 deletion in a patient with juvenile myelomonocytic leukemia, developmental delay, and multiple malformations: a case report. BMC Med Genomics 2018;11:60. DOI: https://doi.org/10.1186/s12920-018-0377-3
Román M, Baraibar I, López I, et al. Gil-Bazo, KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. Mol Cancer 2018;17:33. DOI: https://doi.org/10.1186/s12943-018-0789-x
de Castro Carpeño J, Belda-Iniesta C. KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach, Transl. Lung Cancer Res 2013;2:142-51.
Zhu C, Guan X, Zhang X, et al. Qin, Targeting KRAS mutant cancers: from druggable therapy to drug resistance. Mol Cancer 2022;21:159. DOI: https://doi.org/10.1186/s12943-022-01629-2
Marchetti A, Milella M, Felicioni L, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009;11:1084-92. DOI: https://doi.org/10.1593/neo.09814
Chen YY, Lin KH, Kuo YS, et al. Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma. World J Surg Oncol 2023;21:326. DOI: https://doi.org/10.1186/s12957-023-03203-6
Poulet G, Massias J, Taly V. Liquid biopsy: general concepts. Acta Cytol 2019;63:449-55. DOI: https://doi.org/10.1159/000499337
Wang R, Li Q, Li Z, et al. Apoptosis drives cancer cells proliferate and metastasize. J Cell Mol Med 2013;17:205-11. DOI: https://doi.org/10.1111/j.1582-4934.2012.01663.x
Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cell-free DNA. Cancer Biol Ther 2019;20:1057-67. DOI: https://doi.org/10.1080/15384047.2019.1598759
Crucitta S, Ruglioni M, Novi C, et al. Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer. Clin Chim Acta 2023;541:117239. DOI: https://doi.org/10.1016/j.cca.2023.117239
Venkataram R, Arjuna S, Hosmane GB, Chakraborty A. Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies. Monaldi Arch Chest Dis 2021;91:1748. DOI: https://doi.org/10.4081/monaldi.2021.1748
Nagasaka M, Li Y, Sukari A, et al. KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat Rev 2020;84:101974. DOI: https://doi.org/10.1016/j.ctrv.2020.101974
Goulding RE, Chenoweth M, Carter GC, et al. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: a systematic literature review and meta-analysis. Cancer Treat Res. Commun 2020;24:100200. DOI: https://doi.org/10.1016/j.ctarc.2020.100200
De Maglio G, Pasello G, Dono M, et al. The storm of NGS in NSCLC diagnostic-therapeutic pathway: How to sun the real clinical practice. Crit Rev Oncol Hematol 2022;169:103561. DOI: https://doi.org/10.1016/j.critrevonc.2021.103561
Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol 2021;32:466-77. DOI: https://doi.org/10.1016/j.annonc.2021.01.074
Kahlert C. Liquid biopsy: is there an advantage to analyzing circulating exosomal DNA compared to cfDNA or are they the same? Cancer Res 2019;79:2462-5. DOI: https://doi.org/10.1158/0008-5472.CAN-19-0019
Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014;6:224ra24.
Aggarwal S, Patil S, Minhans S, Pungliya M. A study of EGFR mutation in nonsmoker NSCLC: Striking disparity between north and south India patients. J Cloin Oncol 2012;30:e18041. DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.e18041
Unni AM, Lockwood WW, Zejnullahu K, et al. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Elife 2015;4:e06907. DOI: https://doi.org/10.7554/eLife.06907
Schwartz C, Khan M, Nguyen R, et al. P76.33 concurrent EGFR and KRAS mutations in lung adenocarcinoma: a single institution case series. J Thorac Oncol 2021;16:S600-1. DOI: https://doi.org/10.1016/j.jtho.2021.01.1090
Benesova L, Minarik M, Jancarikova D, et al. Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors. Anticancer Res 2010;30:1667-71.
Sousa V, Rodrigues C, Silva M, et al. Lung adenocarcinoma: sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status. Rev Port Pneumol 2015;21:113-25. DOI: https://doi.org/10.1016/j.rppnen.2014.09.009
Marino FZ, Bianco R, Accardo M, et al. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications. Int J Med Sci 2019;16:981-9. DOI: https://doi.org/10.7150/ijms.34739
Visser E, de Kock R, Genet S, et al. Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer. Transl Oncol 2023;27:101589. DOI: https://doi.org/10.1016/j.tranon.2022.101589
Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med 2016;13:3-11. DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0004
Nacchio M, Sgariglia R, Gristina V, et al. KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting. J Thorac Dis 2020;12:3836-43. DOI: https://doi.org/10.21037/jtd.2020.01.19
Otto S, Mensel B, Friedrich N, et al. Predictors of technical success and rate of complications of image-guided percutaneous transthoracic lung needle biopsy of pulmonary tumors. PLoS One 2015;10:e0124947. DOI: https://doi.org/10.1371/journal.pone.0124947
Fois SS, Paliogiannis P, Zinellu A, et al. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int J Mol Sci 2021;22:612. DOI: https://doi.org/10.3390/ijms22020612
Chen H, Huang D, Lin G, et al. The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐mutant non‐small cell lung cancer. Cancer Med 2022;11:3581-92. DOI: https://doi.org/10.1002/cam4.4739
Jia Y, Jiang T, Li X, et al. Characterization of distinct types of KRAS mutation and its impact on first‑line platinum‑based chemotherapy in Chinese patients with advanced non‑small cell lung cancer. Oncol Lett 2017;14:6525-32. DOI: https://doi.org/10.3892/ol.2017.7016
Liu SY, Sun H, Zhou JY, et al. Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients. Biomark Res 2020;8:22. DOI: https://doi.org/10.1186/s40364-020-00199-z
Isaksson J, Berglund A, Louie K, et al. KRAS G12C mutant non–small cell lung cancer linked to female sex and high risk of CNS metastasis: population-based demographics and survival data from the National Swedish Lung Cancer Registry. Clin Lung Cancer 2023;24:507-18. DOI: https://doi.org/10.1016/j.cllc.2023.05.002
Balaram G, Thomas R, Ghorpade SN, et al. Kirsten rat sarcoma mutation in South Indians with non-small lung cancer: a cause for concern? J Precis Oncol 2022;2:3-8. DOI: https://doi.org/10.4103/jpo.jpo_7_22
Ethics approval
The study was approved by the Institutional Ethics Committee (REG. NO. EC/NEW/INST/2020/ 834) of KS Hegde Medical Academy which is a constituent institution of Nitte (Deemed to be University) Approval ID: INST.EC/EC/147/2020-21 dated 16.01.2021.How to Cite
“Non-Invasive Profiling of KRAS Mutations in Lung Cancer Using Droplet Digital Polymerase Chain Reaction”. 2025. Monaldi Archives for Chest Disease, September. https://doi.org/10.4081/monaldi.2025.3190.
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.